Anemia Due to CKD
Anemia Due to CKD Affects Over 1.8 Million Patients in the United States
Anemia is a serious medical condition in which there is insufficient hemoglobin in the blood to deliver oxygen to organs and tissue. Untreated anemia is associated with chronic fatigue, increased risk of progression of multiple comorbidities, and death.
To learn more about anemia due to CKD, please visit the following links:
Current Treatment Options
Anemia due to CKD is currently treated with injectable erythropoiesis-stimulating agents (ESAs), such as epoetin alfa and darbepoetin alfa, as well as with iron supplementation or red blood cell transfusion. ESAs deliver supra-physiological levels of erythropoietin to stimulate production of red blood cells and are injected under the skin (subcutaneously) or into a vein (intravenously).
Injectable ESAs, while effective in raising hemoglobin levels, have safety risks. Several landmark studies have shown an increased risk of cardiovascular events, stroke, and death associated with the use of ESAs. As a result, there is a need for alternative treatment options.
Opening the Door for a Potential New Approach to Renal Anemia
We believe that new treatment options are needed. Vadadustat, a HIF stabilizer, is designed to mimic the body’s own adaptive response to hypoxia.
Akebia is currently evaluating the safety and efficacy of vadadustat for the treatment of anemia due to CKD in a global Phase 3 program.
Vadadustat is an investigational drug and has not yet been approved by the US Food and Drug Administration (FDA) or any regulatory authority.